Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
Clopidogrel is an effective new antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease. However, the mechanism of clopidogrel action is not well understood, although it is known to inhibit ADP-evoked platelet aggregation. In the current study, the effect of clopidogrel on recently identified human platelet ADP receptors and their signaling pathways was investigated by using platelets from clopidogrel-treated subjects, 6 healthy volunteers (2 females and 4 males) who received 75 mg of clopidogrel daily for 7 days. Blood was taken and various platelet receptor signaling pathways were analyzed before treatment, after 7 days of medication, and 4 weeks after treatment had ceased. Platelet tests included the analysis of aggregation, rapid calcium influx, calcium mobilization from intracellular stores, adenylyl cyclase, and phosphorylation of vasodilator-stimulated phosphoprotein (VASP). The data indicate that clopidogrel does not affect those platelet ADP receptors coupled to cation influx (P2X1 ADP receptors) or calcium mobilization (P2Y1 ADP receptors). In contrast, clopidogrel treatment specifically impairs the ADP receptor coupled to G(i)/adenylyl cyclase (P2Y(AC) ADP receptors). Clopidogrel abolishes the inhibitory P2Y(AC) receptor-mediated ADP effects on prostaglandin E(1)-stimulated, cAMP-dependent phosphorylation of VASP without affecting epinephrine, thrombin, and thromboxane signaling. VASP phosphorylation is known to be closely correlated with the inhibition of platelet and fibrinogen receptor (glycoprotein IIb/IIIa) activation. Therefore, inhibition of the platelet P2Y(AC) ADP receptor and its intracellular signaling, including decreased VASP phosphorylation, is suggested as a molecular mechanism of clopidogrel action.
Geiger
J
J
Institute of Clinical Biochemistry, Department of Cardiology, Medical University Clinic, Würzburg, Germany.
Brich
J
J
Hönig-Liedl
P
P
Eigenthaler
M
M
Schanzenbächer
P
P
Herbert
J M
JM
Walter
U
U
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000527:Alprostadil / Q000037:antagonists & inhibitors; D001792:Blood Platelets / Q000737:chemistry; D002118:Calcium / Q000502:physiology; D000077144:Clopidogrel; D000242:Cyclic AMP / Q000097:blood; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D010750:Phosphoproteins; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D000242:Cyclic AMP; D000527:Alprostadil; D013988:Ticlopidine; D002118:Calcium; D004837:Epinephrine